Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Subscribe To Our Newsletter & Stay Updated